ReviewPharmaceutical nanotechnology2026
A Comprehensive Review on Strategies of Topical Niosomes and Their Synergistic Effect for Enhanced Therapeutic Outcomes.
Review in Pharmaceutical nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The review aims to assess the potential of niosomes-nonionic surfactant-based vesicular systems-as carriers for topical and transdermal drug delivery. Niosomes enable targeted and controlled drug release while minimizing systemic toxicity. The investigation centers on their structure, stability, and capacity to entrap both hydrophilic and lipophilic drugs, as well as their use in managing various dermatological and systemic disorders. Recent studies have examined the formulation of niosomes, particularly highlighting the roles of nonionic surfactants and cholesterol in enhancing the stability and entrapment efficiency of these vesicles. Research on permeability enhancers has been reviewed for their ability to work together to improve drug transport and bioavailability. It also provides a detailed discussion on the use of niosomes in treating various dermatological conditions, as well as their applications in systemic diseases, with a particular focus on co-delivery systems in cancer therapies. Niosomes exhibit efficacy in drug delivery by providing an increase in penetration through the stratum corneum, targeting hydrophilic and lipophilic drugs for dermatological and systemic applications. The Development of niosomal therapy has expanded into immunization, antiinflammatory treatments, and the control of pigmentation. Permeability enhancers further increase their efficacy, bioavailability, and tissue localization. Anticancer treatment using niosomes for codelivery of agents demonstrates synergistic effects with reduced side effects. Niosomes have tremendous potential in advancing topical and transdermal drug delivery, offering controlled, targeted release and improved patient outcomes. With optimized fabrication and comprehensive toxicity evaluation, niosomes can potentially revolutionize topical therapies, making them safer, more effective, and patient-friendly for a range of next-generation treatment options across dermatology and beyond.
Indexed as
Identifiers
39757616What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.